Quantcast
Home > Quotes > APTX

Aptinyx Inc. Common Stock (APTX) Quote & Summary Data

APTX 
$20.7399
*  
0.4999
2.47%
Get APTX Alerts
*Delayed - data as of Dec. 19, 2018 9:43 ET  -  Find a broker to begin trading APTX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    APTX Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 20.70 / $ 20.91
1 Year Target
33.5
Today's High / Low
$ 20.7399 / $ 20.07
Share Volume
2,991
50 Day Avg. Daily Volume
78,518
Previous Close
$ 20.24
52 Week High / Low
$ 32.25 / $ 17.35
Market Cap
694,731,565
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-0.5

Intraday Chart

Shares Traded

Share Volume:
2,991
50 Day Avg. Daily Volume:
78,518

Trading Range

The current last sale of $20.7399 is 19.54% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 20.7399 $ 32.25
 Low: $ 20.07 $ 17.35

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. We focus our efforts on targeting and modulating N-methyl-D-aspartate receptors, or NMDArs, which are vital to normal and effective function of the brain and nervous system. We believe leveraging the therapeutic advantages of the differentiated modulatory mechanism of our compounds will drive a paradigm shift in the treatment of disorders of the brain and nervous system. We are advancing a pipeline of distinct product candidates derived from our NMDAr modulator discovery platform, or discovery platform. This platform enables us to discover compounds that have the potential to modulate NMDArs optimally. We are currently studying our first product candidate, NYX-2925, in two Phase 2 studies in chronic pain.  ... More ...  


Risk Grade

Where does APTX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 20.07
Open Date:
Dec. 19, 2018
Close Price:
$ 20.24
Close Date:
Dec. 18, 2018

Consensus Recommendation

Analyst Info